By Adria Calatayud
FRANKFURT (Dow Jones)–Sanofi and Johnson & Johnson’s Janssen Pharmaceuticals division have entered into a development and commercialization agreement for a vaccine candidate against extraintestinal pathogenic Escherichia coli. The French pharmaceutical company announced on Tuesday that it will make an upfront payment of $175 million to vaccine developer Janssen, followed by milestone payments for development and commercialization. Both parties will co-finance current and future research and development costs. Sanofi and Janssen want to share the profits made from the vaccine in the US, France, Germany, Italy, Spain and Great Britain, while Janssen is to receive tiered royalties and sales milestones in the rest of the world.
The vaccine is currently in a late-stage clinical trial that was started by Janssen in 2021 and is continuing to enroll patients, Sanofi said. Extraintestinal pathogenic E. coli is a major cause of antimicrobial resistance.
Contact the author: [email protected]
DJG/DJN/cbr/err
(END) Dow Jones Newswires
October 03, 2023 02:17 ET (06:17 GMT)
Selected leverage products on Johnson Johnson
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Johnson Johnson
The leverage must be between 2 and 20
Advertising